Related Experiment Video

Updated: Jun 2, 2026

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

Update of the management of inflammatory bowel disease

J M E Fell1

  • 1Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK. j.fell@imperial.ac.uk

Archives of Disease in Childhood
|April 21, 2011
PubMed

Insights

Pediatric inflammatory bowel disease, including Crohn's disease and ulcerative colitis, affects up to 25% of patients. Special considerations for growth and long-term effects are crucial in managing these young individuals, especially with new therapies like anti-tumour necrosis factor monoclonal agents.

Area of Science:

  • Pediatric Gastroenterology
  • Inflammatory Bowel Disease (IBD) Research
  • Clinical Pediatrics

Background:

  • Inflammatory bowel disease (IBD), encompassing Crohn's disease and ulcerative colitis, frequently manifests in individuals under 18, accounting for up to 25% of all cases.
  • While the underlying disease mechanisms in pediatric IBD mirror those in adults, the unique physiological considerations of growth and development in children necessitate distinct management strategies.
  • The long-term implications of both the disease itself and its therapeutic interventions pose significant challenges in the pediatric population.

Purpose of the Study:

  • To highlight the unique challenges and considerations in managing pediatric inflammatory bowel disease (IBD).
  • To discuss the evolving therapeutic landscape for IBD in children, including the role of novel treatments.
  • To emphasize the importance of addressing growth and long-term consequences in young IBD patients.

Main Methods:

  • Review of current literature on pediatric IBD management.
  • Analysis of the impact of disease and treatment on growth and development.
  • Evaluation of the evolving role and risks of anti-tumour necrosis factor (TNF) monoclonal therapies in pediatric IBD.

Main Results:

  • Pediatric IBD requires tailored management due to growth and long-term sequelae.
  • Anti-tumour necrosis factor (TNF) monoclonal therapies are increasingly utilized but carry specific risks in children.
  • Understanding the long-term consequences of IBD and its treatments is critical for optimizing patient outcomes.

Conclusions:

  • Management of pediatric Crohn's disease and ulcerative colitis demands specialized attention to growth and long-term outcomes.
  • The use of anti-tumour necrosis factor (TNF) monoclonal therapy in pediatric IBD is expanding, necessitating careful risk-benefit assessment.
  • Future research should focus on optimizing long-term management strategies for young IBD patients.

More Related Videos

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis09:44

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...